Bryan, Garnier & Co acts as Sole Financial Advisor to Physidia and its shareholders, a leading European renal care medtech company providing home haemodialysis solutions, on the sale of a majority stake to Columna Capital

Bryan, Garnier & Co acts as Joint Global Coordinator & Joint Bookrunner on Medincell's EUR 25 million Follow-on Offering

Bryan, Garnier & Co acts as Financial Advisor & Placement Agent on Abivax’s EUR 130 million Cross-over Financing

Bryan, Garnier & Co acts as Joint Global Coordinator & Joint Bookrunner on Egetis Therapeutics' Nasdaq Stockholm SEK 210 million Follow-on Offering

Bryan, Garnier & Co acts as Sole Financial Advisor to Selfapy, one of the leading providers in digital therapeutics for mental health disorders in Germany, on its growth financing from strategic investor Medice Arzneimittel and existing shareholders

Bryan, Garnier & Co acts as Sole Bookrunner on Oncodesign Precision Medicine's EUR 8 million Follow-on Offering & IPO on Euronext Growth Paris

Bryan, Garnier & Co acts as Sole Financial Advisor to XVIVO on the acquisition of the Machine & Perfusion division from Avionord S.r.l.

Bryan, Garnier & Co acts as Joint Global Coordinator & Joint Bookrunner on Nicox' Euronext Paris EUR 10 million Follow-on Offering & Warrants issuance

Bryan, Garnier & Co acts as Joint Bookrunner on Valneva’s Nasdaq and Euronext Paris EUR 102.9 million Follow-on Offering

Bryan, Garnier & Co acts as Sole Global Coordinator and Joint Bookrunner on Abivax’s EUR 49 million Cross-over Financing